TD Cowen (formerly Cowen and Company) is one of the most prolific ATM offering agents in U.S. equity markets, representing a significant portion of all active ATM programs. According to DilutionWatch data covering 7,300+ stocks, Cowen serves as ATM agent for approximately 15% of all active ATM programs, with a concentration in biotech, cannabis, and small-cap technology sectors. Understanding Cowen's standard ATM terms helps investors quickly interpret new ATM filings.
Standard Cowen ATM agreements follow a consistent structure. The company grants Cowen the authority to sell shares as agent (not as principal), meaning Cowen acts on the company's behalf rather than buying and reselling shares. The commission rate is typically 3% of gross proceeds, with some variation based on deal size and client relationship. The agreement specifies the maximum aggregate offering amount and references the underlying shelf registration.
Key provisions that investors should examine include the sales parameters section (which outlines how the company controls timing, volume, and minimum prices), the termination provisions (either party can typically terminate with 5-10 days' notice), and the indemnification section (which allocates liability between the company and Cowen). The existence of multiple ATM agents for the same company can indicate more aggressive selling intentions, as multiple agents can sell simultaneously into different venues.
When DilutionWatch detects a new Cowen ATM filing, it automatically calculates the potential dilution, flags the maximum offering amount relative to market cap, and begins monitoring volume patterns for signs of active selling. Cowen ATM filings are particularly noteworthy in the biotech space, where Cowen has deep relationships and often serves as both ATM agent and research analyst, creating potential conflicts of interest that investors should be aware of.
Historical analysis shows that Cowen ATM programs in the biotech sector have an average utilization rate of 72% (meaning companies use approximately 72% of the authorized capacity), with most utilization occurring in the first 18 months. DilutionWatch tracks utilization rates by agent and sector, providing context for assessing how likely a new ATM program is to be fully utilized.
TD Cowen has deep expertise in biotech and small-cap markets, strong institutional distribution, and long-standing relationships with companies that frequently raise capital. Their research coverage of ATM clients also provides visibility for the company's stock.
Standard commission is 3% of gross proceeds, though large programs may negotiate lower rates. This commission is disclosed in the ATM agreement filed as an exhibit to the prospectus supplement.
The agent identity doesn't directly affect price impact. However, Cowen's concentration in biotech means their ATM filings disproportionately affect biotech stocks, where dilution sensitivity is already high. DilutionWatch tracks performance by agent as part of its analytics.
DilutionWatch monitors 7,300+ stocks for dilution risk in real time. Get the DilutionScore™ for any ticker instantly.
Search DilutionWatch →